Why did Allogene cancel two clinical trials for its off-the-shelf cell therapy?
Today's Readout newsletter: Allogene changes gears, Illumina exec leaves to become Delfi CEO, and a Feng Zhang startup lays off a quarter of staff.
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Hello! Today, we discuss why a cell therapy stalwart is pivoting, and why a Feng Zhang startup is laying off a quarter of its staff. Also, Novartis is using some of its GLP-1 windfall to invest in Flagship Pioneering startups in the cardiometabolic space.
What's Your Reaction?
